Paratek Pharmaceuticals’ (PRTK) “Overweight” Rating Reaffirmed at Cantor Fitzgerald
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research note issued on Tuesday. Cantor Fitzgerald also issued estimates for Paratek Pharmaceuticals’ FY2017 earnings at ($3.42) EPS and FY2018 earnings at ($2.59) EPS.
Other equities research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Thursday, April 20th. HC Wainwright lifted their price target on shares of Paratek Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, April 11th. BidaskClub lowered shares of Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Finally, Raymond James Financial, Inc. started coverage on shares of Paratek Pharmaceuticals in a research note on Thursday, May 18th. They issued a “strong-buy” rating and a $36.00 price target on the stock. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Paratek Pharmaceuticals has a consensus rating of “Buy” and an average target price of $37.44.
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) opened at 20.45 on Tuesday. The company’s market capitalization is $564.42 million. Paratek Pharmaceuticals has a one year low of $9.80 and a one year high of $26.10. The company has a 50-day moving average of $22.62 and a 200-day moving average of $19.91.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million during the quarter, compared to analyst estimates of $7.50 million.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/paratek-pharmaceuticals-prtk-overweight-rating-reaffirmed-at-cantor-fitzgerald/1467985.html.
In other news, CFO Douglas W. Pagan sold 4,139 shares of the business’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total transaction of $97,597.62. Following the transaction, the chief financial officer now directly owns 60,000 shares in the company, valued at approximately $1,414,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Adam Woodrow sold 3,800 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $89,604.00. Following the transaction, the vice president now owns 69,500 shares in the company, valued at $1,638,810. The disclosure for this sale can be found here. Insiders have sold a total of 21,960 shares of company stock worth $524,342 over the last 90 days. 4.90% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its position in Paratek Pharmaceuticals by 13.3% in the second quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after buying an additional 687 shares in the last quarter. Falcon Point Capital LLC purchased a new position in Paratek Pharmaceuticals during the first quarter valued at $200,000. Fox Run Management L.L.C. purchased a new position in Paratek Pharmaceuticals during the second quarter valued at $200,000. Russell Investments Group Ltd. purchased a new position in Paratek Pharmaceuticals during the first quarter valued at $211,000. Finally, American International Group Inc. raised its position in Paratek Pharmaceuticals by 34.1% in the first quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock valued at $214,000 after buying an additional 2,824 shares in the last quarter. Institutional investors own 77.36% of the company’s stock.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.